Healthcare provider profile · identity verified

Michael Subik, DPM

Podiatric Medicine & Surgery Service Providers|Podiatrist|Foot & Ankle Surgery · LYNDHURST, NJ · NPI 1003813551

Profile state: payments only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Michael Subik, DPM received $82,469.16 in general payments during 2025 across 104 reported records.

Stryker Corporation accounted for 67.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 27 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$82,469.16

104 reported records · 9 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Stryker Corporation Unresolved — no canonical attribution shown $55,777.0267.6%552025
Orthofix Medical, Inc. Unresolved — no canonical attribution shown $26,181.2631.8%422025
MedShape, Inc. Unresolved — no canonical attribution shown $148.180.2%12025
Davol Inc. Unresolved — no canonical attribution shown $140.690.2%12025
SI-BONE, INC. Unresolved — no canonical attribution shown $104.920.1%12025
Integra LifeSciences Corporation Unresolved — no canonical attribution shown $50.100.1%12025
Reapplix Inc. Unresolved — no canonical attribution shown $44.670.1%12025
Paratek Pharmaceuticals, Inc. Unresolved — no canonical attribution shown $14.620.0%12025
LifeNet Health Unresolved — no canonical attribution shown $7.700.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Consulting Fee$72,763.7020
Travel and Lodging$6,067.0030
Food and Beverage$3,638.4654

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
HOFFMANN
Normalized: hoffmann
Device Stryker Corporation $36,291.57 26 2025
Source payment records
TrueLok
Normalized: truelok
Device Orthofix Medical, Inc. $26,120.74 41 2025
Source payment records
SALVATION
Normalized: salvation
Device Stryker Corporation $24,524.36 5 2025
Source payment records
7 X 23MM CITRELOCK IMPLANT
Normalized: 7 x 23mm citrelock implant
Device Stryker Corporation $4,510.57 4 2025
Source payment records
CITREFIX
Normalized: citrefix
Device Stryker Corporation $3,555.99 5 2025
Source payment records
FLEXBAND
Normalized: flexband
Device Stryker Corporation $3,375.00 1 2025
Source payment records
SONICANCHOR
Normalized: sonicanchor
Device Stryker Corporation $3,375.00 1 2025
Source payment records
SONICPIN
Normalized: sonicpin
Device Stryker Corporation $3,375.00 1 2025
Source payment records
PROSTEP
Normalized: prostep
Device Stryker Corporation $632.06 3 2025
Source payment records
T2
Normalized: t2
Device Stryker Corporation $450.00 1 2025
Source payment records
VALOR
Normalized: valor
Device Stryker Corporation $450.00 1 2025
Source payment records
MAKO
Normalized: mako
Device Stryker Corporation $225.00 1 2025
Source payment records
ACTISHIELD
Normalized: actishield
Device Stryker Corporation $198.67 2 2025
Source payment records
INFINITY ADAPTIS
Normalized: infinity adaptis
Device Stryker Corporation $176.33 2 2025
Source payment records
Channel Drain
Normalized: channel drain
Device Davol Inc. $140.69 1 2025
Source payment records
INBONE
Normalized: inbone
Device Stryker Corporation $135.92 2 2025
Source payment records
PROSTEP MICA
Normalized: prostep mica
Device Stryker Corporation $98.91 2 2025
Source payment records
AXSOS
Normalized: axsos
Device Stryker Corporation $83.64 1 2025
Source payment records
TL-HEX TRUELOK HEXAPOD SYSTEM
Normalized: tl hex truelok hexapod system
Device Orthofix Medical, Inc. $60.52 1 2025
Source payment records
Integra
Normalized: integra
Device Integra LifeSciences Corporation $50.10 1 2025
Source payment records
Integra Dermal Regeneration Template
Normalized: integra dermal regeneration template
Device Integra LifeSciences Corporation $50.10 1 2025
Source payment records
PRIMATRIX
Normalized: primatrix
Device Integra LifeSciences Corporation $50.10 1 2025
Source payment records
3C Patch Kit - Box
Normalized: 3c patch kit box
Device Reapplix Inc. $44.67 1 2025
Source payment records
AUGMENT INJECTABLE
Normalized: augment injectable
Device Stryker Corporation $28.68 1 2025
Source payment records
ORTHOLOC 3DI
Normalized: ortholoc 3di
Device Stryker Corporation $17.87 1 2025
Source payment records
NUZYRA
Normalized: nuzyra
Drug Paratek Pharmaceuticals, Inc. $14.62 1 2025
Source payment records
TheraGenesis Wound Matrix
Normalized: theragenesis wound matrix
Device LifeNet Health $7.70 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $82,469.16 · 104 records Stryker Corporation 3C Patch Kit - Box, 7 X 23MM CITRELOCK IMPLANT, ACTISHIELD, AUGMENT INJECTABLE, AXSOS, CITREFIX, Channel Drain, FLEXBAND, HOFFMANN, INBONE, INFINITY ADAPTIS, Integra, Integra Dermal Regeneration Template, MAKO, NUZYRA, ORTHOLOC 3DI, PRIMATRIX, PROSTEP, PROSTEP MICA, SALVATION, SONICANCHOR, SONICPIN, T2, TL-HEX TRUELOK HEXAPOD SYSTEM, TheraGenesis Wound Matrix, TrueLok, VALOR
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error